Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200031/S013

Organ Care System (OCS) Liver

TransMedics, Inc. · Decision date May 13, 2026

FDA DECISIONP200031/S013

What did the FDA approve?

FDA records P200031/S013 as a supplement to PMA P200031, with the supplement type “Real-Time Process”. The recorded decision is approval, dated May 13, 2026.

FDA approval order statement

approval for material, supplier, and design changes to the filter cap and raw material and supplier changes to the pleated filter assembly
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
May 13, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P200031/S013
Regulatory pathway
PMA supplement
Product code
QQK
Decision code
APPR
Decision date
May 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.

Product code
QQK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200031/S011 · Related supplement

    Organ Care System (OCS) Liver

  2. P200031/S013 received

    Application receipt date recorded by FDA.

  3. P200031/S012 · Related supplement

    Organ Care System (OCS) Liver

  4. P200031/S014 · Related supplement

    Organ Care System (OCS) Liver

  5. P200031/S013 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P200031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200031

Product / regulatory recordCompanyPathwayDecision dateSource
TransMedics, Inc.PMA supplementOct 22, 2025FDA
TransMedics, Inc.PMA supplementDec 16, 2025FDA
TransMedics, Inc.PMA supplementMar 9, 2026FDA

Explore the linked device profile

Other records with product code QQK

Product / regulatory recordCompanyPathwayDecision dateSource
Organox LimitedPMA supplementOct 9, 2026FDA
Organox LimitedPMA supplementAug 7, 2026FDA
Organox LimitedPMA supplementJul 8, 2026FDA
Organox LimitedPMA supplementJul 7, 2026FDA
Organox LimitedPMA supplementJun 5, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

TransMedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
200 Minuteman Rd., Suite 302, Andover, MA, 01810

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records